STK11 mutation is emerging as a biomarker associated with CPI resistance in NSCLC.43,44 Interestingly, we observed that two out of four patients with STK11 mutations had a clinical benefit in our study, which might suggest an anecdotal clinical activity signal of the trial treatment in this population. Here, STK11 is linked to non-small cell lung carcinoma.